Xofigo Ra-223 Radiophamaceutical

This is a combined synopsis/solicitation for commercial items in accordance with FAR Subpart 13 prepared with the format in Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested and a written solicitation will not be issued. The VA Palo Alto Healthcare System (VAPAHCS) has a need to supply Ra-223 Dichloride (Xofigo®) radiopharmaceutical used in the treatment of select patients with metastatic prostate cancer. .



Solicitation number #VA261-17-Q-1257 is issued as a Request for Quotation (RFQ).



The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-95 effective January, 20, 2017.



There is no set-aside provisions associated with this procurement; NAICS code # 325412 and size standard is 1250 employees.

Only electronic offers will be accepted. Offers are due to joleo.dianala@va.gov by September 28, 2017, 5:00 PM. Pacific Time.



The following clauses and provisions applies to this acquisition:



1. 52.212-1, Instructions to Offerors - Commercial (with addenda)

2. 52.212-2, Evaluation - Commercial Items

3. 52.212-3, Offeror Representations and Certifications - contractors are advised to include a completed copy of this provision with their quote

4. 52.212-4, Contract Terms and Conditions-Commercial Items

5. 52.212-5, Contract Terms Required To Implement Statutes Or Executive Orders Commercial Items